Galderma has raised its full-year 2026 earnings guidance following better-than-expected first-half results. The company cited strong demand for Restylane and Dysport in key markets, particularly in Asia, and improved operational efficiency. The guidance increase signals management confidence in sustained momentum through year-end.
Business & M&A
Galderma Raises Full-Year 2026 Earnings Guidance
Stronger-than-expected H1 performance prompts upward revision of profit outlook.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Raised guidance often precedes price increases—review your rebate agreements now.
This matters operationally. When major manufacturers raise guidance, they typically increase production capacity and accelerate new product launches to capture upside. Practices should expect steady or improved product availability and potentially new formulations or line extensions from Galderma's portfolio in the second half of 2026. Conversely, raised guidance often precedes price increases as companies lock in margin gains. Owners should review their Galderma rebate agreements and per-unit economics now, before any pricing action.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.